Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 2
1969 1
1971 1
1972 7
1973 1
1974 2
1975 1
1976 2
1977 4
1979 3
1982 11
1983 304
1984 957
1985 1090
1986 1143
1987 1240
1988 1349
1989 1476
1990 1597
1991 1483
1992 1510
1993 1582
1994 1616
1995 1681
1996 1753
1997 1817
1998 1772
1999 1905
2000 2020
2001 1996
2002 2225
2003 2378
2004 2581
2005 2910
2006 3025
2007 2924
2008 3074
2009 3286
2010 3884
2011 4096
2012 4204
2013 4326
2014 4691
2015 4802
2016 4024
2017 3770
2018 4000
2019 2131
2020 118
Text availability
Article attribute
Article type
Publication date

Search Results

83,076 results
Results by year
Filters applied: . Clear all
Page 1
Chemotherapy in the oldest old: Choices and outcomes.
van Walree IC, van Breukelen ELG, Thielen N, van Rens MTM, van Huis-Tanja LH, Hamaker ME. van Walree IC, et al. Eur J Cancer Care (Engl). 2019 Jul;28(4):e13049. doi: 10.1111/ecc.13049. Epub 2019 Apr 29. Eur J Cancer Care (Engl). 2019. PMID: 31033091
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.
Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A Jr, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ; U.S. Expanded Access Program Investigators. Sartor O, et al. Oncologist. 2018 Feb;23(2):193-202. doi: 10.1634/theoncologist.2017-0413. Epub 2017 Nov 28. Oncologist. 2018. PMID: 29183960 Free PMC article. Clinical Trial.
Combined anticancer therapies: an overview of the latest applications.
Piccolo MT, Menale C, Crispi S. Piccolo MT, et al. Anticancer Agents Med Chem. 2015;15(4):408-22. doi: 10.2174/1871520615666150113123039. Anticancer Agents Med Chem. 2015. PMID: 25584691 Review.
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.
Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsirigotis P, Vassou A, Vervessou E, Katodritou E, Gika D, Terpos E, Dimopoulos MA. Kastritis E, et al. Blood. 2015 Sep 10;126(11):1392-4. doi: 10.1182/blood-2015-05-647420. Blood. 2015. PMID: 26359434 Clinical Trial. No abstract available.
Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan.
Morita S, Kikumori T, Tsunoda N, Inaishi T, Adachi Y, Ota A, Shibata M, Matsuoka A, Nakanishi K, Takeuchi D, Mizutani T, Shimokata T, Hayashi H, Maeda O, Ando Y. Morita S, et al. Int J Clin Oncol. 2018 Feb;23(1):195-200. doi: 10.1007/s10147-017-1177-z. Epub 2017 Aug 8. Int J Clin Oncol. 2018. PMID: 28791509 Clinical Trial.
[Chemotherapy risk assessment for elderly patients].
Gao HL, Bai CM. Gao HL, et al. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2014 Oct;36(5):551-5. doi: 10.3881/j.issn.1000-503X.2014.05.019. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2014. PMID: 25360657 Free article. Review. Chinese.
Dabrafenib-trametinib combination in 'field-practice': an Italian experience.
Depenni R, De Rosa F, Greco S, Ridolfi L, Pellacani G, Ponti G, Cascinu S, Guidoboni M. Depenni R, et al. Future Oncol. 2018 Aug;14(20):2045-2052. doi: 10.2217/fon-2017-0714. Epub 2018 Aug 7. Future Oncol. 2018. PMID: 30081673
83,076 results
Jump to page
Feedback